Voyager Therapeutics, Inc. (VYGR) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 3.72 |
| Open | 3.68 |
| Day High | 3.82 |
| Day Low | 3.68 |
| 52-Week High | 5.55 |
| 52-Week Low | 2.83 |
| Volume | 565,927 |
| Average Volume | 540,259 |
| Market Cap | 224.77M |
| PE | -1.87 |
| EPS | -1.99 |
| Moving Average 50 Days | 3.8 |
| Moving Average 200 Days | 4.09 |
| Change | -0 |
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
GlobeNewswire Inc.
Nov 10, 2025 1:01 PM GMT
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates, and Voyager Therapeutics (Na
Voyager to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 26, 2025 11:00 AM GMT
LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the followi
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
GlobeNewswire Inc.
Jul 16, 2025 11:00 AM GMT
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s wholly-owned Alzheimer’s disease franchise now include